EUCTR2005-001721-29-DE进行中（未招募）不适用
An Open-Label, Single-Arm, Multi-Center, Phase II/III study of Troxatyl (Troxacitabine) Administered by Continuous Infusion in Patients with Acute Myeloid Leukemia (AML) in second salvage
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 211
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients must have a confirmed diagnosis of Acute Myeloid Leukemia according to the World Health Organization (WHO) classification (except for acute promyelocytic leukemia (APL)).
- •- Patient must have received at least two previous coursed of induction chemotherapy to be considered in the second salvage setting i.e. 1) have never achieved CR or CRp with two prior different cytotoxic induction regimens, or 2) have relapsed after a first CR or CRp and failed to respond to a cytotoxic first salvage therapy, or 3) have relapsed after < 6 months from a second CR or CRp
- •- Patient bone marrow aspirates and/or biopsies must contain >= 10% blasts.
- •- Previous bone marrow transplantation patients will be allowed.
- •-Leukemia relapse or persistence must be confirmed by recurrence of blasts in peripheral blood, bone marrow histopathology and/or histological proven extramedullary disease.
- •- There is no restriction on number of regimens or type of treatment administered for consolidation in first or second CR (or CRp).
- •- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of <= 2 and an estimated life expectancy of at least eight weeks.
- •- Patients must be >= 18 years old.
- •- Male, or female patients who are post-menopausal (amenorrhagic for at least 12 months), or surgically or biologically sterile. Females of childbearing potential with a negative serum pregnancy test prior to entering the study and using adequate forms of contraception for the duration of the study, including 30 days after the last treatment. Males should avoid fathering children during the course of the study, and adequate methods of contraception should be used by both male and female patients. Patients and their partners with reproductive potential must use an effective contraceptive method while the patient is on the study treatment and for 30 days after the last treatment. Adequate methods of contraception are double barrier methods (condoms with spermicidal jelly or foam, birth control patch /e.g., Ortho Evra), NuvaRing, and diaphragm with spermicidal jelly or foam), oral, depot and injectable contraceptives, IUD, and surgical sterilization. Single barrier methods, rhythm methods, will not be
- •considered adequate contraception .
- •- Patients must have following laboratory values:
- •Parameter LaboratoryValues
- •Estimated Serum creatinine clearance>=45 mL/min
- •Total Bilirubin <= 2.0mg/dL (<= 34.2µmol/L)
- •AST (SGOT) or ALT (SGPT) <= or equal 3 X ULN*
- •*ULN: Institution’s upper limit of normal.
- •- The patient must understand and be able and willing and likely to fully comply with study procedures, including scheduled follow-up.
- •- The patient must have given written personally signed and dated informed consent to participate in the study, in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines, before completing any study related procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Ongoing clinical significant toxicities from previous treatments for AML.
- •- Patients who have experienced a Grade 3/4 skin rash or any grade hand -foot syndrome with prior anti-leukemia therapy.
- •- Clinical evidence of active CNS leukemic involvement.
- •- Active and uncontrolled infection. Patients with infections that are under active treatment with antibiotics and whose infections are controlled may be entered to the study. Patients with chronic hepatitis are eligible.
- •- Clinical evidence by tumor marker, pathology, or radiological studies of an active second malignancy.
- •- Uncontrolled medical problems, unrelated to the malignancy, or of sufficient severity that in the opinion of the investigator, impair a patient’s ability to give informed consent or unacceptably reduce the safety of the proposed treatment.
- •- Neurological or psychiatric disorders that would interfere with consent or study follow-up.
- •- Known or suspected intolerance or hypersensitivity to the study materials [or closely related compounds], lamivudine, or any of the stated ingredients including mannitol within the study materials.
- •- Patients with a history of alcohol or other substance abuse within the last year will be excluded.
- •- Patients cannot have received any treatment other than hydroxyurea as second salvage. Hydroxyurea should be discontinued at least 24 hours prior to initiation of protocol treatment.
- •- Female patients who are pregnant or lactating or females with a positive pregnancy test at screening must be excluded.
研究者
相似试验
招募中
不适用
A Phase 2 study of Pemetrexed/Cisplatin Chemotherapy for Patients With Metastatic/Recurrent Soft Tissue SarcomaNeoplasmsKCT0005369Yonsei University Health System, Severance Hospital164
进行中（未招募）
1 期
A multicenter, open-label, single-arm, phase II trial exploring the maintenance of trastuzumab and pertuzumab following trastuzumab deruxtecan as induction treatment for HER2-positive unresectable locally recurrent or metastatic breast cancer patients.CTIS2023-507306-13-00Medica Scientia Innovation Research S.L.132
招募中
2 期
Phase II, Multi-Center, Open-Label, Single-Arm Study Evaluating the Efficacy and Safety of Mycophenolate Mofetil in Patients with High-Grade Locally Advanced or Metastatic Osteosarcoma (ESMMO)High-grade locally advanced or metastatic osteosarcomaOsteosarcomaTCTR20190701001Faculty of Medicine, Chiang Mai University27
进行中（未招募）
不适用
An Open-Label, Single-Arm, Multi-Center, Phase 2 Study of Troxatyl troxacitabine Administered by Continuous Infusion in Patients with Acute Myeloid Leukemia AML in Second SalvagePatients with Acute Myeloid Leukemia AML in second salvageMedDRA version: 9.1Level: LLTClassification code 10000880Term: Acute myeloid leukaemiaEUCTR2005-001721-29-ITSTRUCTURAL GENOMIX211
进行中（未招募）
2 期
Clinical Study of Plasma-Derived Factor VIII/VWF in Subjects with Congenital Hemophilia A and InhibitorsCTRI/2017/04/008336Spectrum Clinical Research Pvt Ltd